Feel The Vibe: SocialVibe.com Empowers Libby’s H*O*P*E* To Raise Money For Cancer Research

Today, Libby’s H*O*P*E*™ added a new widget to the homepage right sidebar.  The widget, provided by SocialVibe.com, allows our sponsor, the TNT Network, to make donations to Stand Up To Cancer, which is our supported cause.  Here’s how it works.  For each visitor who comes to our website and clicks on the widget to interact with the TNT Network brand, TNT makes a donation on our behalf directly to Stand Up To Cancer.  Better yet, it’s all free to Libby’s H*O*P*E*™ and our visitors.  It provides you, the visitor, with a way to support cancer research without having to make an actual cash donation.

Today, Libby’s H*O*P*E*™ added a new widget to the homepage right sidebar.  The widget, provided by SocialVibe.com, allows our sponsor, the TNT Network, to make donations to Stand Up To Cancer, which is our supported cause.  Here’s how it works.  For each visitor who comes to our website and clicks on the widget to interact with the TNT Network brand, TNT makes a donation on our behalf directly to Stand Up To Cancer.  Better yet, it’s all free to Libby’s H*O*P*E*™ and our visitors.  It provides you, the visitor, with a way to support cancer research without having to make an actual cash donation. Please note that Libby’s H*O*P*E*™ does not receive any monetary benefit from SocialVibe or TNT for displaying the widget.

Upon clicking our SocialVibe widget, you will be asked to answer the question “Who’s Your Hero,” and you will be able to view upcoming previews from TNT’s new television series entitled HawthoRNe, which stars Jada Pinkett Smith. Pinkett Smith plays Christina Hawthorne, a compassionate and headstrong Chief Nursing Officer, who leads a group of dedicated nurses at the fictional Richmond Trinity Hospital.  Hawthorne is the kind of nurse that you want on your side when you or someone you love is in the hospital. She is the kind of nurse who fights for her patients and does not let them slip through the cracks. When necessary, she takes on doctors and administrators who are overworked, distracted or just unable to see the human being behind the hospital chart.

I chose TNT as the initial Libby’s H*O*P*E*™ sponsor because both of my sisters are dedicated nurses who have spent many years caring for patients being treated in various hospital departments such as the emergency room, operating room, and intensive care unit.

We will change the sponsor from time to time so that our visitors can interact with different brands periodically.  We hope that you enjoy interacting with the SocialVibe.com widget while raising money for cancer research.

2009 ASCO Annual Meeting Highlights: Ovarian Cancer & Select General Issues

The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Orlando, Florida from May 29 through June 2, 2009.  We provide below select highlights from the 2009 ASCO Annual Meeting that relate to ovarian cancer and other general issues.

The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Orlando, Florida from May 29 through June 2, 2009.  We provide below select highlights from the 2009 ASCO Annual Meeting that relate to ovarian cancer and other general issues. Learn more about How to Read a Medical Abstract in a Research Study.

Development Time of Cancer Clinical Trials Linked to Accrual Goals.

Physicians Need to Address Prescription Costs With Patients Who Participate In Clinical Trials.

Availability of Experimental Therapy Outside of Randomized Clinical Trials In Oncology.

ASCO Fertility Preservation Guidelines For Cancer Patients Not Widely Followed By Oncologists.

Ginger (Zindol®) Quells Cancer Patients’ Chemotherapy-Related Nausea.

Early Treatment of Recurrent Ovarian Cancer Based Upon Rising CA-125 Levels Does Not Increase Survival.

Body Mass Index (BMI) Should Be Taken Into Account When Assessing A Cancer Patient’s Vitamin D Status.

Extreme Drug Resistance (EDR) Assay Results Do Not Independently Predict Or Alter The Outcomes of Patients With Epithelial Ovarian Cancer Who Are Treated With Optimal Cytoreductive Surgery Followed By Platinum & Taxane Combination Chemotherapy in Either a Primary or Recurrent Setting.

Systematic Review Of Past Study Results For Use of Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Preliminary Results From Phase II Study of Oxaliplatin+Docetaxel+Bevacizumab As First Line Treatment of Advanced Ovarian Cancer Show 62% Overall Response Rate & 70% One-Year Progression Free Survival.

Combined Weekly Docetaxel + Gemcitabine In Relapsed Ovarian Cancer & Peritoneal Cancer Produces 59% Overall Response Rate.

A Phase II Trial of Irinotecan & Oral Etoposide Chemotherapy in Recurrent Ovarian Cancer Patients Produces 47% Overall Response Rate & 81% Clinical Benefit Rate.

Weekly Bevacizumab & Pegylated Liposomal Doxorubicin Produce 55% Clinical Benefit Rate In Progressing/Recurrent Ovarian Cancer Patients.

Phase II Study of Belotecan (CKD-602)+ Carboplatin Demonstrates 53% Overall Response Rate in Recurrent Ovarian Cancer Patients.

Single Agent Voreloxin Produces 11% Overall Response Rate & 52% Disease Control Rate in Phase II Study Involving Women with Platinum-Resistant Ovarian Cancer.

A Phase II Study of Patupilone In Patients With Platinum Refractory/Resistant Ovarian, Primary Fallopian, or Peritoneal Cancer Produces 48% Clinical Benefit Rate.

Trabectedin (Yondelis®) + Pegylated Liposomal Doxorubicin (PLD) Produces Better Response Than PLD Alone.

M.D. Anderson Cancer Center Finds Anti-VEGF Therapy Is Highly Effective In Patients With Ovarian Granulosa Cell Tumors.

M.D. Anderson Cancer Center Finds That Increased Angiogenesis Is A Significant Predictor Of Poor Clinical Outcome In Patients With Sex-Cord Stromal Tumors; Suggests Anti-Angiogenesis Therapy is Warranted For This Subtype of Ovarian Cancer.

ZYBRESTAT™ (Combretastatin A-4 phosphate) Produces 32% Confirmed Partial Response Rate (RR) in Evaluable Patients With Platinum Resistant Ovarian Cancer (25% RR if total enrolled patients used as denominator).

ASSIST-5 Trial of TELCYTA® + Pegylated Liposomal Doxorubicin Produces 12% Response Rate (With One Complete Response) in Patients With Platinum Refractory and Resistant Ovarian Cancer.

Two Studies Provide Contradictory Data for Use of Carboplatin + Pegylated Liposomal Doxorubicin in Ovarian Cancer

OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase I Cancer Trial, Including 60% Response Rate (Based Upon Declining CA125) For Ovarian Cancer Patients.

Maintenance BIBF 1120 Could Delay Disease Progression in Recurrent Ovarian Cancer.

Oral PARP Inhibitor Olaparib (AZD2281) Effective Against BRCA-Deficient Advanced Ovarian Cancer.

Carfilzomib (PX-171-007) Produces Stable Disease For 4+ Months In One Ovarian Cancer Patient Who Failed Under Four Previous Treatment Lines – Phase II Solid Tumor Trial.

__________________________________________

About The American Society of Clinical Oncology

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. To view 2009 ASCO Annual Meeting presentation abstracts, click here.  To view 2009 ASCO Annual Meeting presentation abstracts regarding ovarian cancer, click here.  To view ASCO ovarian cancer information, click here.

About Cancer.Net

Cancer.Net, formerly People Living With Cancer (PLWC), brings the expertise and resources of the American Society of Clinical Oncology (ASCO), the voice of the world’s cancer physicians, to people living with cancer and those who care for and care about them. ASCO is composed of more than 27,000 oncologists globally who are the leaders in advancing cancer care. All the information and content on Cancer.Net was developed and approved by the cancer doctors who are members of ASCO, making Cancer.Net the most up-to-date and trusted resource for cancer information on the Internet. Cancer.Net is made possible by The ASCO Cancer Foundation, which provides support for cutting-edge cancer research, professional education, and patient information.

Cancer.Net provides timely, oncologist-approved information to help patients and families make informed health-care decisions. All content is subject to a formal peer-review process by the Cancer.Net Editorial Board, composed of more than 150 medical, surgical, radiation, and pediatric oncologists, oncology nurses, social workers, and patient advocates. In addition, ASCO editorial staff reviews the content for easy readability. Cancer.Net content is reviewed on an annual basis or as needed.

To view Cancer.Net ovarian cancer information, click here.

Learn more about How to Read a Medical Abstract in a Research Study, Cancer.Net.

One In Three Billion Found: Single Mutation In FOXL2 Gene May Cause Granulosa Cell Ovarian Cancer

“… Vancouver scientists from the Ovarian Cancer Research (OvCaRe) Program at BC Cancer Agency and Vancouver Coastal Health Research Institute have discovered that there appears to be a single spelling mistake in the genetic code of granulosa cell tumours, a rare and often untreatable form of ovarian cancer. This means that out of the three billion nucleotide pairs that make up the genetic code of the tumour, one – the same one in every tumour sample – is incorrect. The discovery, published online June 10th in the New England Journal of Medicine, marks the beginning of a new era of cancer genomics, where the complete genetic sequence of cancers can be unravelled and the mutations that cause them exposed. For women with granulosa cell tumours it represents the first specific diagnostic tool and clear path to develop much needed treatments for this cancer. …”

Found: One in Three Billion

The spelling mistake in the genetic code that causes a type of Ovarian Cancer

Eureka! Vancouver scientists from the Ovarian Cancer Research (OvCaRe) Program at BC Cancer Agency and Vancouver Coastal Health Research Institute have discovered that there appears to be a single spelling mistake in the genetic code of granulosa cell tumours, a rare and often untreatable form of ovarian cancer. This means that out of the three billion nucleotide pairs that make up the genetic code of the tumour, one – the same one in every tumour sample – is incorrect. The discovery, published online June 10th in the New England Journal of Medicine, marks the beginning of a new era of cancer genomics, where the complete genetic sequence of cancers can be unravelled and the mutations that cause them exposed. For women with granulosa cell tumours it represents the first specific diagnostic tool and clear path to develop much needed treatments for this cancer.

Dr. David Huntsman

David Huntsman, M.D. (Nfld.), Associate Professor, Department of Pathology & Laboratory Medicine, University of British Columbia; Genetic Pathologist, BC Cancer Agency

“This is really a two-fold discovery,” says Dr. David Huntsman, lead author and genetic pathologist at the BC Cancer Agency and Vancouver General Hospital and associate professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia. “It clearly shows the power of the new generation of DNA sequencing technologies to impact clinical medicine, and for those of us in the area of ovarian cancer research and care, by identifying the singular mutation that causes granulosa cell tumours, we can now more easily identify them and develop news ways to treat them.”

In the past when scientists wanted to look at the sequence of a tumour, it was a laborious process, with each gene individually decoded into thousands of nucleotides and all data accumulated and sorted. Most studies could only look at one or at most a few of the 20,000 genes in the human genome whereas the new sequencing technologies allow scientists to look at everything at once. Through a collaboration between OvCaRe and the BC Cancer Agency’s Genome Sciences Centre, the research team used “next generation” sequencing machines that are able to decode billions of nucleotides at rapid speed and new computer techniques to quickly assemble the data. “This task would have been unfathomable in terms of both cost and complexity even two years ago,” says Dr. Marco Marra, Director of the BC Cancer Agency’s Genome Sciences Centre.

The OvCaRe team decoded four tumour samples of the relatively rare granulosa cell tumour, which affects five percent of ovarian cancer patients. Using the new sequencing technology and bioinformatics, they discovered a single nucleotide located in the FOXL2 gene was mutated in every sample. The research team further validated their work by examining a large number [95 samples] of additional tumour samples from across Canada and around the world, and are satisfied they have been able to validate that this mutation is present in almost all granulosa cell tumours and not in unrelated cancers. Most types of cancers, including ovarian cancers, have a broad range of genetic abnormalities. This finding shows that granulosa cell tumours have a characteristic single DNA spelling mistake that can serve as an easy to read identity tag for this cancer type.

“Although it has been suggested that hundreds of any cancer type would have to be sequenced at great depth to make clinically useful discoveries,” says Huntsman, “we had hypothesized that knowledge could be gained from much smaller studies if the cancers were carefully selected and represented clinically homogenous diseases. There are many rarer cancer types, like granulosa cell tumours that fit that bill and based upon our success in decoding granulosa cell tumours we are focusing on other rare tumours in what could be described as a guerrilla war on cancer. We hope that these studies will not only help future patients with rare tumours but will also teach us about more common ones as well.”

“This cancer is unique,” says Dr. Dianne Miller, gynecologic oncologist at BC Cancer Agency and Vancouver General Hospital. “For patients with this tumour type, it means they should all have the same response to the same treatment. And now that we have this pathway, we can look for existing cancer drugs that might work on this particular gene mutation to make the cancer disappear.”

The OvCaRe team was able to make this discovery because of the multidisciplinary nature of the group, which crosses two provincial health authorities and is made up of gynaecologists, pathologists, bioinformatics specialists, and oncologists. Further enhancing the team’s success is the centralization of patient treatment and record keeping.

“We are excited by this paper,” says Dr. Michael Birrer, professor, Department of Medicine, Harvard Medical School and director GYN/Medical Oncology, Medicine, Massachusetts General Hospital. “The ovarian cancer research and care community now has new biologic insights into this poorly understood tumour and a potential therapeutic target. More importantly, this tour de force study reveals the power of genomic approaches to cancer, particularly rare tumours.”

Ovarian cancer affects about one in 70 Canadian women. Approximately 2500 new cases are diagnosed each year and the five-year survival rate is only 30 per cent.

This study was supported by donors to VGH & UBC Hospital Foundation and the BC Cancer Foundation, and Genome BC for the development of Illumina sequencing at the BC Cancer Agency’s Genome Sciences Centre. OvCaRe and the BC Cancer Agency’s Genome Sciences Centre are also supported by the Michael Smith Foundation for Health Research.

Ovarian Cancer Research Program (OvCaRe) is a multidisciplinary research program involving clinicians and research scientists in gynaecology, pathology, and medical oncology. OvCaRe is a unique collaboration between the BC Cancer Agency, Vancouver Coastal Health Research Institute, and the University of British Columbia. Funding is provided through donations to VGH & UBC Hospital Foundation and the BC Cancer Foundation, who, in a joint partnership created a campaign to raise funds to make OvCaRe possible. The OvCaRe team is considered a leader in ovarian cancer research, breaking new ground in better identifying, understanding, and treating this disease. Earlier this year, the team discovered that ovarian cancer was not just one disease, but rather made up of several distinct subtypes.

Primary Sources:

Related N Engl J Med Editorial:  Shendure J, Stewart, CJ. Cancer Genomes on a Shoestring Budget. N Engl J Med 2009 0: NEJMe0903433 (Full Text).

Additional Reference:  Köbel M, Kalloger SE, Boyd N,et. al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008 Dec 2;5(12):e232. PubMed PMID: 19053170; PubMed Central PMCID: PMC2592352.

Additional Resources:

Gloria Johns Was Told “Ovarian Cancer Patients Don’t Live Long Enough … To Have Support Groups;” She Proved Otherwise

Every so often, you come across a story of hope, courage, and dogged perseverance that renews the spirit and lifts the soul.  Gloria Johns’ story is a classic example.  Gloria Johns is a 61 year old stage IV ovarian cancer survivor, who has battled the disease for nine years through five cancer recurrences.  When Gloria inquired about enrolling in an ovarian cancer support group after her initial diagnosis, she was informed by a local health care professional that “[o]varian cancer patients don’t live long enough … to have support groups.”  Gloria Johns proved otherwise by establishing the first ovarian cancer support group in Alachua County, Florida (which encompasses the city of Gainsville). … Recently, Gloria’s inspirational story was featured in an online article (reprinted in full below) written by Jessica Chapman for The High Springs Herald.

Every so often, you come across a story of hope, courage, and dogged perseverance that renews the spirit and lifts the soul.  Gloria Johns’ story is a classic example.  Gloria Johns is a 61 year old stage IV ovarian cancer survivor, who has battled the disease for nine years through five cancer recurrences.  When Gloria inquired about enrolling in an ovarian cancer support group after her initial diagnosis, she was informed by a local health care professional that “[o]varian cancer patients don’t live long enough … to have support groups.”  Gloria Johns proved otherwise by establishing the first ovarian cancer support group in Alachua County, Florida (which encompasses the city of Gainsville).  Always encouraging, Gloria tells the women in her support group to “never take a day for granted,” while reminding them to ignore statistics because “women with ovarian cancer are not numbers.”

Recently, Gloria’s inspirational story was featured in an online article (reprinted in full below) written by Jessica Chapman for the The High Springs Herald. At the end of the story, Gloria states:  “My goal in life now is to help others on this journey and give them hope to overcome. … I believe with all my heart that God has ordained this for my life to make me the person he wants me to be.”  Ralph Waldo Emerson, the great American poet and essayist, wrote: “… [T]o leave the world a better place…to know even one life has breathed easier because you have lived. This is to have succeeded.” By any measure, Gloria Johns has succeeded.  Gloria’s ongoing support group work represents not only a job well done, but a life well spent.

We want to extend special thanks to The High Springs Herald, Jessica Chapman (author), and Edward Izquierdo (photographer) for allowing us to reprint Gloria Johns’ inspirational story.  We also want to thank Gloria Johns for her living example of courage, perseverance, and most importantly, hope.

___________________________________________

Johns’ beats cancer five times, forms support group that no one said could exist

By Jessica Chapman For The High Springs Herald, High Springs, Florida.

ALACHUA — In 2002, at 2 p.m., Gloria Johns’ eyes rolled back in her head, and she was gone. Then she was floating above her body, watching as doctors worked on her.

Her platelet count had just dropped to four. A patient’s platelet count is at a dangerous level when it is below 10.

When she woke up at 10 p.m., the nurse told her someone had sat with her all day. The woman with long, blond hair never said anything. The nurse thought it was Johns’ daughter, but it wasn’t.

She walked into the elevator just as Johns woke up.

Johns believes an angel sat with her until she woke up.

Photo By Edward Izquierdo. When Gloria Johns first attempted to form a support group for ovarian cancer patients, she was told they don't live long enough to join a support group. She proved otherwise and has the photos (above) to show it.

Photo By Edward Izquierdo. When Gloria Johns first attempted to form a support group for ovarian cancer patients, she was told they don't live long enough to join a support group. She proved otherwise and has the photos (above) to show it.

In 2000, Johns, 61, was diagnosed with stage IV ovarian cancer. For nine years, she fought through five recurrences of cancer.

And beat them all.

Throughout all the support from friends and family over the years, one thing Johns didn’t have when she first began treatment was a support group that could relate to what she was going through.

“I went to the patient liaison at North Florida (Regional Medical Center) to get one (a support group when she was first diagnosed), and she [the patient liaison] said, ‘Ovarian cancer patients don’t live long enough for us to have support groups,’” Johns recalled as she sat at the dining table in her kitchen. “That was discouraging.”

Ovarian cancer is the fifth most common cancer-related death among women. That is more deaths than any other cancer of the female reproductive system, according to the American Cancer Society.

After her third recurrence with cancer, which is when her heart stopped, she decided to start her own support group, the first ovarian cancer support group in Alachua County [Florida].

Johns, who has lived in the Alachua area for 13 years, mentioned the support group to her doctor, who thought it was a wonderful idea, and she started the group, Johns elaborated.

Before support groups for ovarian cancer and the success in cancer research began, tips like the ones these women share were few and far between, Johns said.

Ovarian cancer was known as the “silent killer” because by the time it was detected, it usually had spread to other areas of the body, according to the Mayo Clinic.

“Only about 20 percent of ovarian cancers are found before tumor growth has spread beyond the ovaries,” according to the Mayo Clinic.

“It’s overwhelming what cancer is doing to people,” Johns added. “It changes you.”

Along with encouraging the women in her support group to “never take a day for granted,” she reminds them to not look at statistics. Women with ovarian cancer are not numbers, she said.

Statistics include a wide range of people. The women in statistics include the young, old, those with different stages of cancer and those with multiple recurrences, Johns said.

For example, those statistics might not be true for a young woman in stage two of cancer, she elaborated.

Johns does believe that encouraging and supporting people can help prevent future ovarian cancer-related deaths. Johns frequently e-mails and calls other ovarian cancer patients throughout the country in need of support.

Many of the people who contact her have heard of her through oncology offices throughout Gainesville [Florida].

But while much of her time is spent encouraging other cancer patients, she makes sure to take care of herself, too. She has a rule: after one of the women has gone to hospice or home to family, she will not go see them, but she will call.

“I think that would be extremely detrimental,” she said. “I’ve never done that. I’ve been real careful about getting extremely close to people.”

Six women in the group have died. She has called and sent cards to them all, but she prefers not to talk about them.

Despite the hardships and losses, Johns has learned an important lesson in her journey with cancer: everything has a purpose, she said.

She believes that God’s purpose for her was to use her experiences with cancer to help and encourage the women facing the same problems.

Through five recurrences with cancer, five different treatments, five times losing her hair, five times facing the fear of dying, Johns could have used the support from the group she started.

“The first recurrence is worse than the first time in my opinion,” Johns said. “The first recurrence is tough because you were praying you’d beat this thing.”

The first treatment she received was nine months of carboplatin and taxol chemotherapy. After she went through these chemotherapy treatments, she was in remission for 10 months. Then the cancer came back, and she had three more chemotherapy treatments during her first recurrence.

“It never held a whole year,” Johns said. “It seemed to come back every August.

When the cancer came back two years later, she had a stem cell transplant at Moffitt Cancer Center in Tampa.

“You’re so weak (after the transplant) you can’t work,” she said. “You can’t be around animals. You can’t be around dirt because your immune system is so shattered there’s just nothing there.”

However, a weak immune system didn’t slow her down. When Johns returned home, she kept up with her regular activities, including teaching the college and career Sunday school class and leading the church choir at Antioch Baptist Church in LaCrosse.

The treatment was supposed to keep cancer from coming back for four years, but despite her hard work at returning to a normal life, the cancer came back two years after the treatment.

She, again, went through six months of chemotherapy, but the cancer came back in less than a year. This is when she went into anaphylactic shock. The anaphylactic shock was a result of too much chemotherapy over the past years.

After recovering, she decided that as long as she was in remission from the one and a half chemotherapy treatments she received, she would give her body a rest and stop treatment.

Almost three years passed before the cancer came back for the last recurrence in 2007, but this time she was prepared, Johns said.

Johns and her doctors knew that if the cancer came back, she would go through CyberKnife radiation, a new treatment previously used on brain tumors. The doctors were unable to use radiation on ovarian cancer patients until the CyberKnife radiation treatments began.

Her energy level went up after the radiation, and as a result, she felt “like myself again,” she said.

Ever since that treatment, she has been in remission. Thanksgiving 2008 marked two years in remission.

“I’ve been trying to get there for eight and a half years,” she said.

Now, Johns said she makes sure to appreciate her time, and she knows that if she loses the fight with cancer, as a result of her support group, something will be left behind “that was worth doing.”

“My goal in life now is to help others on this journey and give them hope to overcome,” Johns said. “I believe with all my heart that God has ordained this for my life to make me the person he wants me to be.”

SourceJohns’ beats cancer five times, forms support group that no one said could exist, by Jessica Chapman, News section, The High Springs Herald, published online May 29, 2009.  The article and accompanying photograph were republished by Libby’s H*O*P*E*™ with the permission of the The High Springs Herald, Jessica Chapman (the author) and Edward Izquierdo (the photographer).

Gene Network Sciences, UConn To Work On Computer-Modeled Ovarian Cancer Treatments

Gene Network Sciences, Inc. (GNS) today announced that it has entered into a research collaboration with The University of Connecticut Health Center’s Carole and Ray Neag Comprehensive Cancer Center in which the parties will incorporate genetic, genomic and clinical data (“3-D Data”) together into computer models of different cancers [with ovarian cancer as initial area of focus] to be used to identify the best treatments for individual patients and to develop new drug treatments and diagnostics.

Gene Network Sciences Announces Cancer Collaboration with University of Connecticut Health Center’s Neag Comprehensive Cancer Center

CAMBRIDGE, Mass., June 3 — Gene Network Sciences, Inc. (GNS) today announced that it has entered into a research collaboration with The University of Connecticut Health Center’s Carole and Ray Neag Comprehensive Cancer Center in which the parties will incorporate genetic, genomic and clinical data (“3-D Data”) together into computer models of different cancers to be used to identify the best treatments for individual patients and to develop new drug treatments and diagnostics. Financial terms were not disclosed.

runowicz

Carolyn D. Runowicz, M.D., Director, Neag Comprehensive Cancer Center, Univ. of Conn. Health Center; Chair, National Cancer Advisory Board

Tom Neyarapally, Senior VP, Corporate Development, Gene Network Sciences, Inc.

GNS and the Neag Comprehensive Cancer Center began their collaboration as a result of a connection made last year between two University of Connecticut alumni from different generations, Dr. Carolyn Runowicz (a graduate of the College of Liberal Arts and Sciences in the 1970s) and Tom Neyarapally (a graduate of the School of Engineering in the 1990s). Runowicz, who served as President of the American Cancer Society from 2005-2006 and is currently Director of the Neag Comprehensive Cancer Center, and Neyarapally identified ovarian cancer as an initial area of focus. Runowicz and Neyarapally are also, together with colleagues Drs. Molly Brewer and Iya Khalil, preparing a scientific publication regarding ovarian cancer treatment and the use of computational modeling capabilities such as GNS’s supercomputing-driven REFS(TM)[Reverse Engineering/Foward Simulation] platform to improve treatments and outcomes. The parties are also in the process of assembling a consortium in ovarian cancer with additional cancer centers that have yet to be named.

“With ever-increasing quantities of molecular and genetic data from cancer patients becoming available, we as clinicians are in great need of capabilities to optimally and rapidly utilize this information,” said Dr. Runowicz. “We are excited to link up with GNS, which has created a unique supercomputer-driven technology platform to turn this information directly into simulation models, and ultimately better treatments, for cancer patients.”

The parties will utilize the Neag Comprehensive Cancer Center’s clinical expertise to assess and validate findings from the ovarian cancer model simulations and will work with strategic partners to make drugs and diagnostics created based on these discoveries available to patients. They are also currently in discussions regarding the application of the REFS(TM) platform in other cancers such as prostate cancer.

“GNS is looking forward to working with the Neag Comprehensive Cancer Center’s extremely talented cancer researchers to rapidly convert data into actionable computer models of different cancers and clinical insights,” said Neyarapally, Senior Vice President of Corporate Development at GNS. “We feel privileged to be working closely with Dr. Runowicz, an established leader in the fight against cancer.”

About Gene Network Sciences

Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data. Based in Cambridge, Massachusetts, and Ithaca, New York, GNS uses its REFS(TM) technology in pharmaceutical and clinical settings to rapidly turn combinations of genetic, genomic, and clinical measurements into models of disease progression and drug response. These models are then simulated to discover both new targets for drug intervention and genetic markers of drug response that allow patients who will respond to a given drug treatment to be matched to a particular clinical trial. By discovering how and why specific sets of genes and drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.

About The University of Connecticut Health Center

The University of Connecticut Health Center includes the schools of medicine and dental medicine, the UConn Medical Group, University Dentists, and John Dempsey Hospital. Founded in 1961, the Health Center pursues a mission of providing outstanding health care education in an environment of exemplary patient care, research and public service. To learn more about the UConn Health Center, visit our website at http://www.uchc.edu.

Contact:
Thomas Neyarapally
Gene Network Sciences
(617) 494-0492
tneyarapally@gnsbiotech.com

SourceGene Network Sciences announces a cancer collaboration with the University of Connecticut Health Center’s NEAG Comprehensive Cancer Center, Press Release, June 3, 2009.